APO Research
Talk to an analyst

APO RESEARCH · REPORT

Therapeutic Peptide APIs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Therapeutic Peptide APIs Market Outlook and Growth Opportunities 2026

27 December 2025217 pages

Choose your research edition.

Industry ResearchTherapeutic Peptide APIs Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal Therapeutic Peptide APIs Industry Growth and Trends Forecast to 2032125 pages · $3,450 USDMarket StructureGlobal Therapeutic Peptide APIs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Therapeutic Peptide APIs Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Therapeutic Peptide APIs Market Analysis and Forecast 2026-2032211 pages · $4,950 USD

Market perspective

The global Therapeutic Peptide APIs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Therapeutic Peptide APIs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Therapeutic Peptide APIs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Therapeutic Peptide APIs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Therapeutic Peptide APIs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Therapeutic Peptide APIs market include AmbioPharm, Aspen API, Bachem, Bio Basic, CordenPharma, CPC Scientific, GenScript, JPT Peptide Technologies and Limitless Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Therapeutic Peptide APIs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Therapeutic Peptide APIs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Therapeutic Peptide APIs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Therapeutic Peptide APIs market size, projected growth trends, production technologies, key applications, and end-use industries.

Therapeutic Peptide APIs Segment by Company

AmbioPharm

Aspen API

Bachem

Bio Basic

CordenPharma

CPC Scientific

GenScript

JPT Peptide Technologies

Limitless Biotech

Lonza

Piramal Pharma

PolyPeptide

ScinoPharm

Syngene

USV Peptides

Hybio Pharmaceutical

Guangdong Jianyuan Pharmaceutical

Jiangsu Sinopep-Allsino Biopharmaceutical

Zhejiang Peptites Biotech

Cheng Du Sheng Nuo Biotec

Hainan Shuangcheng Pharmaceuticals

Therapeutic Peptide APIs Segment by Type

Bioactive Peptides

Synthetic Peptides

Therapeutic Peptide APIs Segment by Application

Pharmaceuticals

Scientific Research

Other

Therapeutic Peptide APIs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Therapeutic Peptide APIs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Therapeutic Peptide APIs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Therapeutic Peptide APIs significant trends, drivers, influence factors in global and regions.

6. To analyze Therapeutic Peptide APIs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Peptide APIs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Peptide APIs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Peptide APIs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Therapeutic Peptide APIs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Peptide APIs industry.

Chapter 3: Detailed analysis of Therapeutic Peptide APIs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Therapeutic Peptide APIs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Therapeutic Peptide APIs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Therapeutic Peptide APIs Industry Trends Table 2. Therapeutic Peptide APIs Industry Drivers Table 3. Therapeutic Peptide APIs Industry Opportunities and Challenges Table 4. Therapeutic Peptide APIs Industry Restraints Table 5. Global Therapeutic Peptide APIs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Therapeutic Peptide APIs Revenue Share by Company (2021-2026) Table 7. Global Therapeutic Peptide APIs Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Therapeutic Peptide APIs Sales Volume Share by Company (2021-2026) Table 9. Global Therapeutic Peptide APIs Average Price (US$/K G) of Company (2021-2026) Table 10. Global Therapeutic Peptide APIs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Therapeutic Peptide APIs Key Company Manufacturing Base & Headquarters Table 12. Global Therapeutic Peptide APIs Company, Product Type & Application Table 13. Global Therapeutic Peptide APIs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Therapeutic Peptide APIs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Bioactive Peptides Table 18. Significant Companies of Synthetic Peptides Table 19. Global Therapeutic Peptide APIs Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 20. Global Therapeutic Peptide APIs Sales Volume by Type (2021-2026) & (Tons) Table 21. Global Therapeutic Peptide APIs Sales Volume by Type (2027-2032) & (Tons) Table 22. Global Therapeutic Peptide APIs Sales Volume Share by Type (2021-2026) Table 23. Global Therapeutic Peptide APIs Sales Volume Share by Type (2027-2032) Table 24. Global Therapeutic Peptide APIs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Therapeutic Peptide APIs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Therapeutic Peptide APIs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Therapeutic Peptide APIs Sales Value Share by Type (2021-2026) Table 28. Global Therapeutic Peptide APIs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Pharmaceuticals Table 30. Significant Companies of Scientific Research Table 31. Significant Companies of Other Table 32. Global Therapeutic Peptide APIs Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 33. Global Therapeutic Peptide APIs Sales Volume by Application (2021-2026) & (Tons) Table 34. Global Therapeutic Peptide APIs Sales Volume by Application (2027-2032) & (Tons) Table 35. Global Therapeutic Peptide APIs Sales Volume Share by Application (2021-2026) Table 36. Global Therapeutic Peptide APIs Sales Volume Share by Application (2027-2032) Table 37. Global Therapeutic Peptide APIs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Therapeutic Peptide APIs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Therapeutic Peptide APIs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Therapeutic Peptide APIs Sales Value Share by Application (2021-2026) Table 41. Global Therapeutic Peptide APIs Sales Value Share by Application (2027-2032) Table 42. Global Therapeutic Peptide APIs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 43. Global Therapeutic Peptide APIs Sales by Region (2021-2026) & (Tons) Table 44. Global Therapeutic Peptide APIs Sales Market Share by Region (2021-2026) Table 45. Global Therapeutic Peptide APIs Sales by Region (2027-2032) & (Tons) Table 46. Global Therapeutic Peptide APIs Sales Market Share by Region (2027-2032) Table 47. Global Therapeutic Peptide APIs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Therapeutic Peptide APIs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Therapeutic Peptide APIs Sales Value Share by Region (2021-2026) Table 50. Global Therapeutic Peptide APIs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Therapeutic Peptide APIs Sales Value Share by Region (2027-2032) Table 52. Global Therapeutic Peptide APIs Market Average Price (US$/K G) by Region (2021-2026) Table 53. Global Therapeutic Peptide APIs Market Average Price (US$/K G) by Region (2027-2032) Table 54. Global Therapeutic Peptide APIs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 55. Global Therapeutic Peptide APIs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Therapeutic Peptide APIs Sales by Country (2021-2026) & (Tons) Table 57. Global Therapeutic Peptide APIs Sales Market Share by Country (2021-2026) Table 58. Global Therapeutic Peptide APIs Sales by Country (2027-2032) & (Tons) Table 59. Global Therapeutic Peptide APIs Sales Market Share by Country (2027-2032) Table 60. Global Therapeutic Peptide APIs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Therapeutic Peptide APIs Sales Value Market Share by Country (2021-2026) Table 62. Global Therapeutic Peptide APIs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Therapeutic Peptide APIs Sales Value Market Share by Country (2027-2032) Table 64. AmbioPharm Company Information Table 65. AmbioPharm Business Overview Table 66. AmbioPharm Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 67. AmbioPharm Therapeutic Peptide APIs Product Portfolio Table 68. AmbioPharm Recent Development Table 69. Aspen API Company Information Table 70. Aspen API Business Overview Table 71. Aspen API Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 72. Aspen API Therapeutic Peptide APIs Product Portfolio Table 73. Aspen API Recent Development Table 74. Bachem Company Information Table 75. Bachem Business Overview Table 76. Bachem Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 77. Bachem Therapeutic Peptide APIs Product Portfolio Table 78. Bachem Recent Development Table 79. Bio Basic Company Information Table 80. Bio Basic Business Overview Table 81. Bio Basic Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 82. Bio Basic Therapeutic Peptide APIs Product Portfolio Table 83. Bio Basic Recent Development Table 84. CordenPharma Company Information Table 85. CordenPharma Business Overview Table 86. CordenPharma Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 87. CordenPharma Therapeutic Peptide APIs Product Portfolio Table 88. CordenPharma Recent Development Table 89. CPC Scientific Company Information Table 90. CPC Scientific Business Overview Table 91. CPC Scientific Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 92. CPC Scientific Therapeutic Peptide APIs Product Portfolio Table 93. CPC Scientific Recent Development Table 94. GenScript Company Information Table 95. GenScript Business Overview Table 96. GenScript Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 97. GenScript Therapeutic Peptide APIs Product Portfolio Table 98. GenScript Recent Development Table 99. JPT Peptide Technologies Company Information Table 100. JPT Peptide Technologies Business Overview Table 101. JPT Peptide Technologies Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 102. JPT Peptide Technologies Therapeutic Peptide APIs Product Portfolio Table 103. JPT Peptide Technologies Recent Development Table 104. Limitless Biotech Company Information Table 105. Limitless Biotech Business Overview Table 106. Limitless Biotech Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 107. Limitless Biotech Therapeutic Peptide APIs Product Portfolio Table 108. Limitless Biotech Recent Development Table 109. Lonza Company Information Table 110. Lonza Business Overview Table 111. Lonza Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 112. Lonza Therapeutic Peptide APIs Product Portfolio Table 113. Lonza Recent Development Table 114. Piramal Pharma Company Information Table 115. Piramal Pharma Business Overview Table 116. Piramal Pharma Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 117. Piramal Pharma Therapeutic Peptide APIs Product Portfolio Table 118. Piramal Pharma Recent Development Table 119. PolyPeptide Company Information Table 120. PolyPeptide Business Overview Table 121. PolyPeptide Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 122. PolyPeptide Therapeutic Peptide APIs Product Portfolio Table 123. PolyPeptide Recent Development Table 124. ScinoPharm Company Information Table 125. ScinoPharm Business Overview Table 126. ScinoPharm Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 127. ScinoPharm Therapeutic Peptide APIs Product Portfolio Table 128. ScinoPharm Recent Development Table 129. Syngene Company Information Table 130. Syngene Business Overview Table 131. Syngene Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 132. Syngene Therapeutic Peptide APIs Product Portfolio Table 133. Syngene Recent Development Table 134. USV Peptides Company Information Table 135. USV Peptides Business Overview Table 136. USV Peptides Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 137. USV Peptides Therapeutic Peptide APIs Product Portfolio Table 138. USV Peptides Recent Development Table 139. Hybio Pharmaceutical Company Information Table 140. Hybio Pharmaceutical Business Overview Table 141. Hybio Pharmaceutical Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 142. Hybio Pharmaceutical Therapeutic Peptide APIs Product Portfolio Table 143. Hybio Pharmaceutical Recent Development Table 144. Guangdong Jianyuan Pharmaceutical Company Information Table 145. Guangdong Jianyuan Pharmaceutical Business Overview Table 146. Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 147. Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Product Portfolio Table 148. Guangdong Jianyuan Pharmaceutical Recent Development Table 149. Jiangsu Sinopep-Allsino Biopharmaceutical Company Information Table 150. Jiangsu Sinopep-Allsino Biopharmaceutical Business Overview Table 151. Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 152. Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Product Portfolio Table 153. Jiangsu Sinopep-Allsino Biopharmaceutical Recent Development Table 154. Zhejiang Peptites Biotech Company Information Table 155. Zhejiang Peptites Biotech Business Overview Table 156. Zhejiang Peptites Biotech Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 157. Zhejiang Peptites Biotech Therapeutic Peptide APIs Product Portfolio Table 158. Zhejiang Peptites Biotech Recent Development Table 159. Cheng Du Sheng Nuo Biotec Company Information Table 160. Cheng Du Sheng Nuo Biotec Business Overview Table 161. Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 162. Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Product Portfolio Table 163. Cheng Du Sheng Nuo Biotec Recent Development Table 164. Hainan Shuangcheng Pharmaceuticals Company Information Table 165. Hainan Shuangcheng Pharmaceuticals Business Overview Table 166. Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Sales (Tons), Value (US$ Million), Price (US$/K G) and Gross Margin (2021-2026) Table 167. Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Product Portfolio Table 168. Hainan Shuangcheng Pharmaceuticals Recent Development Table 169. Key Raw Materials Table 170. Raw Materials Key Suppliers Table 171. Therapeutic Peptide APIs Distributors List Table 172. Therapeutic Peptide APIs Customers List Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources Table 176. Primary Sources List of Figures Figure 1. Therapeutic Peptide APIs Product Image Figure 2. Global Therapeutic Peptide APIs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Therapeutic Peptide APIs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Therapeutic Peptide APIs Sales (2021-2032) & (Tons) Figure 5. Global Therapeutic Peptide APIs Sales Average Price (US$/K G) & (2021-2032) Figure 6. Global Therapeutic Peptide APIs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Bioactive Peptides Image Figure 10. Synthetic Peptides Image Figure 11. Global Therapeutic Peptide APIs Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 12. Global Therapeutic Peptide APIs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Therapeutic Peptide APIs Sales Volume Share by Type (2021-2032) Figure 14. Global Therapeutic Peptide APIs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Therapeutic Peptide APIs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Therapeutic Peptide APIs Sales Value Share by Type (2021-2032) Figure 17. Pharmaceuticals Image Figure 18. Scientific Research Image Figure 19. Other Image Figure 20. Global Therapeutic Peptide APIs Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 21. Global Therapeutic Peptide APIs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Therapeutic Peptide APIs Sales Volume Share by Application (2021-2032) Figure 23. Global Therapeutic Peptide APIs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Therapeutic Peptide APIs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Therapeutic Peptide APIs Sales Value Share by Application (2021-2032) Figure 26. Global Therapeutic Peptide APIs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 27. Global Therapeutic Peptide APIs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Therapeutic Peptide APIs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Therapeutic Peptide APIs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Therapeutic Peptide APIs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Therapeutic Peptide APIs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Therapeutic Peptide APIs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Therapeutic Peptide APIs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Therapeutic Peptide APIs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Therapeutic Peptide APIs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Therapeutic Peptide APIs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Therapeutic Peptide APIs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Therapeutic Peptide APIs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Therapeutic Peptide APIs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Therapeutic Peptide APIs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Therapeutic Peptide APIs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Bioactive Peptides
  • Synthetic Peptides
Applications
  • Pharmaceuticals
  • Scientific Research
  • Other
Companies covered
  • AmbioPharm
  • Aspen API
  • Bachem
  • Bio Basic
  • CordenPharma
  • CPC Scientific
  • GenScript
  • JPT Peptide Technologies
  • Limitless Biotech
  • Lonza
  • Piramal Pharma
  • PolyPeptide
  • ScinoPharm
  • Syngene
  • USV Peptides
  • Hybio Pharmaceutical
  • Guangdong Jianyuan Pharmaceutical
  • Jiangsu Sinopep-Allsino Biopharmaceutical
  • Zhejiang Peptites Biotech
  • Cheng Du Sheng Nuo Biotec
  • Hainan Shuangcheng Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Therapeutic Peptide APIs Sales Value (2021-2032)
  4. 1.2.2 Global Therapeutic Peptide APIs Sales Volume (2021-2032)
  5. 1.2.3 Global Therapeutic Peptide APIs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Therapeutic Peptide APIs Market Dynamics
  1. 2.1 Therapeutic Peptide APIs Industry Trends
  2. 2.2 Therapeutic Peptide APIs Industry Drivers
  3. 2.3 Therapeutic Peptide APIs Industry Opportunities and Challenges
  4. 2.4 Therapeutic Peptide APIs Industry Restraints
3 Therapeutic Peptide APIs Market by Company
  1. 3.1 Global Therapeutic Peptide APIs Company Revenue Ranking in 2025
  2. 3.2 Global Therapeutic Peptide APIs Revenue by Company (2021-2026)
  3. 3.3 Global Therapeutic Peptide APIs Sales Volume by Company (2021-2026)
  4. 3.4 Global Therapeutic Peptide APIs Average Price by Company (2021-2026)
  5. 3.5 Global Therapeutic Peptide APIs Company Ranking (2024-2026)
  6. 3.6 Global Therapeutic Peptide APIs Company Manufacturing Base and Headquarters
  7. 3.7 Global Therapeutic Peptide APIs Company Product Type and Application
  8. 3.8 Global Therapeutic Peptide APIs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Therapeutic Peptide APIs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Therapeutic Peptide APIs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Therapeutic Peptide APIs Market by Type
  1. 4.1 Therapeutic Peptide APIs Type Introduction
  2. 4.1.1 Bioactive Peptides
  3. 4.1.2 Synthetic Peptides
  4. 4.2 Global Therapeutic Peptide APIs Sales Volume by Type
  5. 4.2.1 Global Therapeutic Peptide APIs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Therapeutic Peptide APIs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Therapeutic Peptide APIs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Therapeutic Peptide APIs Sales Value by Type
  9. 4.3.1 Global Therapeutic Peptide APIs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Therapeutic Peptide APIs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Therapeutic Peptide APIs Sales Value Share by Type (2021-2032)
5 Therapeutic Peptide APIs Market by Application
  1. 5.1 Therapeutic Peptide APIs Application Introduction
  2. 5.1.1 Pharmaceuticals
  3. 5.1.2 Scientific Research
  4. 5.1.3 Other
  5. 5.2 Global Therapeutic Peptide APIs Sales Volume by Application
  6. 5.2.1 Global Therapeutic Peptide APIs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Therapeutic Peptide APIs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Therapeutic Peptide APIs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Therapeutic Peptide APIs Sales Value by Application
  10. 5.3.1 Global Therapeutic Peptide APIs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Therapeutic Peptide APIs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Therapeutic Peptide APIs Sales Value Share by Application (2021-2032)
6 Therapeutic Peptide APIs Regional Sales and Value Analysis
  1. 6.1 Global Therapeutic Peptide APIs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Therapeutic Peptide APIs Sales by Region (2021-2032)
  3. 6.2.1 Global Therapeutic Peptide APIs Sales by Region: 2021-2026
  4. 6.2.2 Global Therapeutic Peptide APIs Sales by Region (2027-2032)
  5. 6.3 Global Therapeutic Peptide APIs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Therapeutic Peptide APIs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Therapeutic Peptide APIs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Therapeutic Peptide APIs Sales Value by Region (2027-2032)
  9. 6.5 Global Therapeutic Peptide APIs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Therapeutic Peptide APIs Sales Value (2021-2032)
  12. 6.6.2 North America Therapeutic Peptide APIs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Therapeutic Peptide APIs Sales Value (2021-2032)
  15. 6.7.2 Europe Therapeutic Peptide APIs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Therapeutic Peptide APIs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Therapeutic Peptide APIs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Therapeutic Peptide APIs Sales Value (2021-2032)
  21. 6.9.2 South America Therapeutic Peptide APIs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Therapeutic Peptide APIs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Therapeutic Peptide APIs Sales Value Share by Country, 2025 VS 2032
7 Therapeutic Peptide APIs Country-level Sales and Value Analysis
  1. 7.1 Global Therapeutic Peptide APIs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Therapeutic Peptide APIs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Therapeutic Peptide APIs Sales by Country (2021-2032)
  4. 7.3.1 Global Therapeutic Peptide APIs Sales by Country (2021-2026)
  5. 7.3.2 Global Therapeutic Peptide APIs Sales by Country (2027-2032)
  6. 7.4 Global Therapeutic Peptide APIs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Therapeutic Peptide APIs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Therapeutic Peptide APIs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Therapeutic Peptide APIs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Therapeutic Peptide APIs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Therapeutic Peptide APIs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AmbioPharm
  2. 8.1.1 AmbioPharm Company Information
  3. 8.1.2 AmbioPharm Business Overview
  4. 8.1.3 AmbioPharm Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AmbioPharm Therapeutic Peptide APIs Product Portfolio
  6. 8.1.5 AmbioPharm Recent Developments
  7. 8.2 Aspen API
  8. 8.2.1 Aspen API Company Information
  9. 8.2.2 Aspen API Business Overview
  10. 8.2.3 Aspen API Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Aspen API Therapeutic Peptide APIs Product Portfolio
  12. 8.2.5 Aspen API Recent Developments
  13. 8.3 Bachem
  14. 8.3.1 Bachem Company Information
  15. 8.3.2 Bachem Business Overview
  16. 8.3.3 Bachem Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bachem Therapeutic Peptide APIs Product Portfolio
  18. 8.3.5 Bachem Recent Developments
  19. 8.4 Bio Basic
  20. 8.4.1 Bio Basic Company Information
  21. 8.4.2 Bio Basic Business Overview
  22. 8.4.3 Bio Basic Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Bio Basic Therapeutic Peptide APIs Product Portfolio
  24. 8.4.5 Bio Basic Recent Developments
  25. 8.5 CordenPharma
  26. 8.5.1 CordenPharma Company Information
  27. 8.5.2 CordenPharma Business Overview
  28. 8.5.3 CordenPharma Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 CordenPharma Therapeutic Peptide APIs Product Portfolio
  30. 8.5.5 CordenPharma Recent Developments
  31. 8.6 CPC Scientific
  32. 8.6.1 CPC Scientific Company Information
  33. 8.6.2 CPC Scientific Business Overview
  34. 8.6.3 CPC Scientific Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 CPC Scientific Therapeutic Peptide APIs Product Portfolio
  36. 8.6.5 CPC Scientific Recent Developments
  37. 8.7 GenScript
  38. 8.7.1 GenScript Company Information
  39. 8.7.2 GenScript Business Overview
  40. 8.7.3 GenScript Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GenScript Therapeutic Peptide APIs Product Portfolio
  42. 8.7.5 GenScript Recent Developments
  43. 8.8 JPT Peptide Technologies
  44. 8.8.1 JPT Peptide Technologies Company Information
  45. 8.8.2 JPT Peptide Technologies Business Overview
  46. 8.8.3 JPT Peptide Technologies Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 JPT Peptide Technologies Therapeutic Peptide APIs Product Portfolio
  48. 8.8.5 JPT Peptide Technologies Recent Developments
  49. 8.9 Limitless Biotech
  50. 8.9.1 Limitless Biotech Company Information
  51. 8.9.2 Limitless Biotech Business Overview
  52. 8.9.3 Limitless Biotech Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Limitless Biotech Therapeutic Peptide APIs Product Portfolio
  54. 8.9.5 Limitless Biotech Recent Developments
  55. 8.10 Lonza
  56. 8.10.1 Lonza Company Information
  57. 8.10.2 Lonza Business Overview
  58. 8.10.3 Lonza Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Lonza Therapeutic Peptide APIs Product Portfolio
  60. 8.10.5 Lonza Recent Developments
  61. 8.11 Piramal Pharma
  62. 8.11.1 Piramal Pharma Company Information
  63. 8.11.2 Piramal Pharma Business Overview
  64. 8.11.3 Piramal Pharma Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Piramal Pharma Therapeutic Peptide APIs Product Portfolio
  66. 8.11.5 Piramal Pharma Recent Developments
  67. 8.12 PolyPeptide
  68. 8.12.1 PolyPeptide Company Information
  69. 8.12.2 PolyPeptide Business Overview
  70. 8.12.3 PolyPeptide Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 PolyPeptide Therapeutic Peptide APIs Product Portfolio
  72. 8.12.5 PolyPeptide Recent Developments
  73. 8.13 ScinoPharm
  74. 8.13.1 ScinoPharm Company Information
  75. 8.13.2 ScinoPharm Business Overview
  76. 8.13.3 ScinoPharm Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 ScinoPharm Therapeutic Peptide APIs Product Portfolio
  78. 8.13.5 ScinoPharm Recent Developments
  79. 8.14 Syngene
  80. 8.14.1 Syngene Company Information
  81. 8.14.2 Syngene Business Overview
  82. 8.14.3 Syngene Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Syngene Therapeutic Peptide APIs Product Portfolio
  84. 8.14.5 Syngene Recent Developments
  85. 8.15 USV Peptides
  86. 8.15.1 USV Peptides Company Information
  87. 8.15.2 USV Peptides Business Overview
  88. 8.15.3 USV Peptides Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 USV Peptides Therapeutic Peptide APIs Product Portfolio
  90. 8.15.5 USV Peptides Recent Developments
  91. 8.16 Hybio Pharmaceutical
  92. 8.16.1 Hybio Pharmaceutical Company Information
  93. 8.16.2 Hybio Pharmaceutical Business Overview
  94. 8.16.3 Hybio Pharmaceutical Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Hybio Pharmaceutical Therapeutic Peptide APIs Product Portfolio
  96. 8.16.5 Hybio Pharmaceutical Recent Developments
  97. 8.17 Guangdong Jianyuan Pharmaceutical
  98. 8.17.1 Guangdong Jianyuan Pharmaceutical Company Information
  99. 8.17.2 Guangdong Jianyuan Pharmaceutical Business Overview
  100. 8.17.3 Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Product Portfolio
  102. 8.17.5 Guangdong Jianyuan Pharmaceutical Recent Developments
  103. 8.18 Jiangsu Sinopep-Allsino Biopharmaceutical
  104. 8.18.1 Jiangsu Sinopep-Allsino Biopharmaceutical Company Information
  105. 8.18.2 Jiangsu Sinopep-Allsino Biopharmaceutical Business Overview
  106. 8.18.3 Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Product Portfolio
  108. 8.18.5 Jiangsu Sinopep-Allsino Biopharmaceutical Recent Developments
  109. 8.19 Zhejiang Peptites Biotech
  110. 8.19.1 Zhejiang Peptites Biotech Company Information
  111. 8.19.2 Zhejiang Peptites Biotech Business Overview
  112. 8.19.3 Zhejiang Peptites Biotech Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Zhejiang Peptites Biotech Therapeutic Peptide APIs Product Portfolio
  114. 8.19.5 Zhejiang Peptites Biotech Recent Developments
  115. 8.20 Cheng Du Sheng Nuo Biotec
  116. 8.20.1 Cheng Du Sheng Nuo Biotec Company Information
  117. 8.20.2 Cheng Du Sheng Nuo Biotec Business Overview
  118. 8.20.3 Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Product Portfolio
  120. 8.20.5 Cheng Du Sheng Nuo Biotec Recent Developments
  121. 8.21 Hainan Shuangcheng Pharmaceuticals
  122. 8.21.1 Hainan Shuangcheng Pharmaceuticals Company Information
  123. 8.21.2 Hainan Shuangcheng Pharmaceuticals Business Overview
  124. 8.21.3 Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Product Portfolio
  126. 8.21.5 Hainan Shuangcheng Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Therapeutic Peptide APIs Value Chain Analysis
  2. 9.1.1 Therapeutic Peptide APIs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Therapeutic Peptide APIs Sales Mode & Process
  6. 9.2 Therapeutic Peptide APIs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Therapeutic Peptide APIs Distributors
  9. 9.2.3 Therapeutic Peptide APIs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst